|
A population-based study of BRCA breast cancer incidence and prognosis in the Italian Emilia Romagna region: The MUTina study. |
| |
|
Honoraria - AstraZeneca; Gilead Sciences; MSD; Novartis; Pfizer |
Consulting or Advisory Role - MSD; Novartis; Pfizer |
Speakers' Bureau - AstraZeneca; Gilead Sciences; MSD Oncology; Novartis |
Travel, Accommodations, Expenses - AstraZeneca; Gilead Sciences |
| |
|
No Relationships to Disclose |
| |
|
Honoraria - Lilly; Pfizer |
Consulting or Advisory Role - Daiichi Sankyo/Astra Zeneca; Lilly; MSD/AstraZeneca; Novartis |
Travel, Accommodations, Expenses - Lilly; Novartis |
| |
|
Honoraria - Istituto Gentili |
Travel, Accommodations, Expenses - Lilly; Novartis Italy |
| |
|
Consulting or Advisory Role - Daiichi Sankyo/Astra Zeneca; Eisai Europe; Lilly; Seagen |
Research Funding - Lilly; Roche (Inst) |
Travel, Accommodations, Expenses - Pfizer |
| |
|
No Relationships to Disclose |
| |
|
No Relationships to Disclose |
| |
|
No Relationships to Disclose |
| |
|
Consulting or Advisory Role - Amgen; AstraZeneca; Celgene; Daichi-Sankyo; EISAI; Exact Sciences; Gilead Sciences; GlaxoSmithKline; Lilly; MSD Oncology; Novartis; Pfizer; PharmaMar; Roche; Seagen |
Research Funding - Abbvie (Inst); Array BioPharma (Inst); AstraZeneca (Inst); Daiichi Sankyo (Inst); Gilead Sciences (Inst); Medivation (Inst); Morphotek (Inst); Novartis (Inst); pfizer (Inst); Roche (Inst); Roche/Genentech (Inst); Seagen (Inst); Synthon (Inst) |
Travel, Accommodations, Expenses - AstraZeneca; Daichi-Sankyo; Gilead Sciences; Novartis; Pfizer; Roche |
| |
|
Consulting or Advisory Role - AstraZeneca; Merck |
Travel, Accommodations, Expenses - Celgene; Ipsen; Pfizer |
| |
|
|
Consulting or Advisory Role - Evotec |
Research Funding - Chiesi; Rigenerand |